Komori
Share Issuance and Disposal4572Carna Biosciences,Inc.Pharmaceuticals

Notice of Completion of Payment for the Issuance of the 5th Series Unsecured Convertible Bonds with Stock Acquisition Rights by Third-Party Allotment

Payment for the 5th Series of Unsecured Convertible Bonds with Stock Acquisition Rights issued through a third-party allotment to Cantor Fitzgerald Europe was completed on 4 November 2026. If all bonds are converted, a maximum of 687,830 shares will be delivered.

Worth reading
58In focus
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
187200000
¥
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of the 5th Series of Unsecured Convertible Bonds with Stock Acquisition Rights through a third-party allotment

Who receives how much687,830Shares

687,830 shares (maximum number of shares to be delivered if all bonds are converted)

Cantor Fitzgerald Europe, 40 units

The lower thin line represents the existing number of shares to which these shares will be added.

Bonds: ¥90 per ¥100 of principal amount; stock acquisition rights: free of charge
Total issue value

Total principal amount of bonds: ¥187,200,000; stock acquisition rights: free of charge

Amount of funds to be raised
Total amount: ¥187,200,000; estimated net proceeds: Not disclosed
Terms of the stock acquisition rights
Exercise price
Conversion price: ¥302.4; no price adjustment provision
Number of Stock Acquisition Rights
Total number issued: 40; number remaining unexercised: Not disclosed
Intended allottee's holding policy
Any transfer requires the company's prior written approval
Payment date
4 November 2026
Most recent equity financing
Timing 14 October 2026 / Type Issuance of new shares through a third-party allotment / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of the 5th Series of Unsecured Convertible Bonds with Stock Acquisition Rights through a third-party allotment
Number of shares to be issued or disposed of687,830 shares (maximum number of shares to be delivered if all bonds are converted)
Issue price and disposal priceBonds: ¥90 per ¥100 of principal amount; stock acquisition rights: free of charge
Total issue valueTotal principal amount of bonds: ¥187,200,000; stock acquisition rights: free of charge
Amount of funds to be raisedTotal amount: ¥187,200,000; estimated net proceeds: Not disclosed
Payment date4 November 2026
Intended allotteeCantor Fitzgerald Europe, 40 units
Intended allottee's holding policyAny transfer requires the company's prior written approval
Exercise priceConversion price: ¥302.4; no price adjustment provision
Number of Stock Acquisition RightsTotal number issued: 40; number remaining unexercised: Not disclosed
Most recent equity financingTiming 14 October 2026 / Type Issuance of new shares through a third-party allotment / Amount Not disclosed
Items this document does not state (17)
Estimated issuance expensesSpecific use of fundsDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because completion of payment was confirmed. This disclosure provides no specific explanation of the use of funds or purpose of the issuance.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for the Issuance of the 5th Series Unsecured Convertible Bonds with Stock Acquisition Rights by Third-Party Allotment | Carna Biosciences,Inc. (4572) timely disclosure | Komori